Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Proof of Concept Study to Evaluate Treatments' Efficacy by Monitoring Minimal Residual Disease Using ctDNA in HR-positive/HER2-negative Early Breast Cancer Population

Next Previous
Trial Profile

A Proof of Concept Study to Evaluate Treatments' Efficacy by Monitoring Minimal Residual Disease Using ctDNA in HR-positive/HER2-negative Early Breast Cancer Population

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abemaciclib (Primary) ; Giredestrant (Primary) ; Inavolisib (Primary)
  • Indications Early breast cancer; HER2 negative breast cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms MiRaDoR

Most Recent Events

  • 05 Mar 2026 Planned number of patients changed from 1260 to 976.
  • 05 Mar 2026 Planned End Date changed from 30 Dec 2028 to 30 Jun 2028.
  • 05 Mar 2026 Planned primary completion date changed from 30 Dec 2028 to 30 Jun 2028.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top